Trials Sponsors Conditions Drugs Pricing

Conditions

Asthma Therapeutic Proteins

Keywords

asthmatherapeuticstherapeutic proteins

Outcome Measures

Primary Outcomes (1)

Number of Lymphocyte
The investigators will compare lymphocyte counts in healthy controls to asthmatics on and off therapeutic proteins.
Up to 18 months

Study Arms (3)

Healthy Controls

Participants with no history of asthma or other lung diseases.

Asthmatics newly prescribed therapeutic proteins

Participants with asthma, have been newly prescribed therapeutic proteins and have yet to start on those therapeutics at the time of enrollment.

Asthmatics already being treated with therapeutic proteins

Participants with asthma who have already started on therapeutic proteins.

Eligibility Criteria

Age18 Years - 80 Years

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Asthmatic patients seen in the outpatient chest faculty practice (clinic) at UCSF Parnassus campus.

You may qualify if:

Male or female between the ages of 18 and 80 years at Visit 1 and at least 50% whose age is \>40 years (to ensure age balance among groups and anticipating that groups 1 and 2 will be older).

Sponsors & Collaborators

University of California, San Francisco
Otherlead
National Heart, Lung, and Blood Institute (NHLBI)
NIHcollaborator

Study Sites (1)

University of California, San Francisco

San Francisco, California, 94143, United States

Biospecimen

Retention: SAMPLES WITH DNA

Blood

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

John V Fahy, MD
University of California, San Francisco
PRINCIPAL INVESTIGATOR

Enrollment

62 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: CROSS SECTIONAL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 12, 2020

First Posted

August 17, 2020

Study Start

November 1, 2020

Actual (reported)

Blood Lymphocytes in Asthmatics Treated With Therapeutic Proteins

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (3)

Healthy Controls

Asthmatics newly prescribed therapeutic proteins

Asthmatics already being treated with therapeutic proteins

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (3)

Healthy Controls

Asthmatics newly prescribed therapeutic proteins

Asthmatics already being treated with therapeutic proteins

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations